Sangamo Therapeutics (SGMO) Competitors $2.05 -0.10 (-4.65%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SGMO vs. ADAP, CLLS, BLUE, ATRA, MNKD, CLDX, DVAX, BCRX, MYGN, and NVAXShould you be buying Sangamo Therapeutics stock or one of its competitors? The main competitors of Sangamo Therapeutics include Adaptimmune Therapeutics (ADAP), Cellectis (CLLS), bluebird bio (BLUE), Atara Biotherapeutics (ATRA), MannKind (MNKD), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), BioCryst Pharmaceuticals (BCRX), Myriad Genetics (MYGN), and Novavax (NVAX). These companies are all part of the "medical" sector. Sangamo Therapeutics vs. Adaptimmune Therapeutics Cellectis bluebird bio Atara Biotherapeutics MannKind Celldex Therapeutics Dynavax Technologies BioCryst Pharmaceuticals Myriad Genetics Novavax Adaptimmune Therapeutics (NASDAQ:ADAP) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, community ranking, risk, valuation, dividends and media sentiment. Does the MarketBeat Community prefer ADAP or SGMO? Sangamo Therapeutics received 130 more outperform votes than Adaptimmune Therapeutics when rated by MarketBeat users. However, 62.95% of users gave Adaptimmune Therapeutics an outperform vote while only 62.55% of users gave Sangamo Therapeutics an outperform vote. CompanyUnderperformOutperformAdaptimmune TherapeuticsOutperform Votes31662.95% Underperform Votes18637.05% Sangamo TherapeuticsOutperform Votes44662.55% Underperform Votes26737.45% Does the media prefer ADAP or SGMO? In the previous week, Adaptimmune Therapeutics had 4 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 24 mentions for Adaptimmune Therapeutics and 20 mentions for Sangamo Therapeutics. Sangamo Therapeutics' average media sentiment score of 0.66 beat Adaptimmune Therapeutics' score of 0.39 indicating that Sangamo Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptimmune Therapeutics 3 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Sangamo Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, ADAP or SGMO? Adaptimmune Therapeutics has a beta of 2.26, indicating that its stock price is 126% more volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Do insiders and institutionals hold more shares of ADAP or SGMO? 31.4% of Adaptimmune Therapeutics shares are held by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are held by institutional investors. 12.4% of Adaptimmune Therapeutics shares are held by insiders. Comparatively, 2.8% of Sangamo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has stronger earnings and valuation, ADAP or SGMO? Adaptimmune Therapeutics has higher earnings, but lower revenue than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Adaptimmune Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdaptimmune Therapeutics$60.28M2.49-$113.87M-$0.22-2.67Sangamo Therapeutics$176.23M2.43-$257.83M-$0.75-2.73 Do analysts rate ADAP or SGMO? Adaptimmune Therapeutics presently has a consensus target price of $3.16, suggesting a potential upside of 439.12%. Sangamo Therapeutics has a consensus target price of $7.00, suggesting a potential upside of 241.46%. Given Adaptimmune Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Adaptimmune Therapeutics is more favorable than Sangamo Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adaptimmune Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Sangamo Therapeutics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Is ADAP or SGMO more profitable? Adaptimmune Therapeutics has a net margin of -25.43% compared to Sangamo Therapeutics' net margin of -257.87%. Adaptimmune Therapeutics' return on equity of -74.15% beat Sangamo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Adaptimmune Therapeutics-25.43% -74.15% -15.09% Sangamo Therapeutics -257.87%-264.16%-107.24% SummaryAdaptimmune Therapeutics beats Sangamo Therapeutics on 14 of the 18 factors compared between the two stocks. Ad Behind the MarketsUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?Click Here to learn how to get in now >>> Get Sangamo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SGMO vs. The Competition Export to ExcelMetricSangamo TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$427.73M$2.93B$5.15B$8.74BDividend YieldN/A1.88%5.18%4.08%P/E Ratio-2.7314.6462.6013.00Price / Sales2.43282.591,277.9088.72Price / Cash55.68169.0039.7935.27Price / Book10.794.006.455.92Net Income-$257.83M-$42.42M$119.73M$225.73M7 Day Performance-28.57%-10.63%-5.13%-1.34%1 Month Performance119.09%-5.81%-2.71%1.15%1 Year Performance432.88%24.19%31.08%24.02% Sangamo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SGMOSangamo Therapeutics2.2761 of 5 stars$2.05-4.7%$7.00+241.5%+484.5%$427.73M$176.23M-2.73480Earnings ReportAnalyst ForecastAnalyst RevisionADAPAdaptimmune Therapeutics2.1677 of 5 stars$0.82+3.8%N/A+17.3%$203.80M$60.28M-2.35449Analyst ForecastAnalyst RevisionNews CoverageCLLSCellectis3.6005 of 5 stars$1.91+7.9%N/A-28.6%$106.16M$9.19M-1.47290Analyst ForecastShort Interest ↓Gap UpHigh Trading VolumeBLUEbluebird bio2.8835 of 5 stars$0.41flatN/A-89.4%$78.59M$29.50M-0.18323Upcoming EarningsAnalyst DowngradeNews CoverageATRAAtara Biotherapeutics3.8526 of 5 stars$11.77+4.1%N/A-0.1%$57.79M$8.57M-0.30165Earnings ReportAnalyst ForecastNews CoverageMNKDMannKind3.9359 of 5 stars$7.22-1.6%N/A+88.9%$1.99B$198.96M103.14400CLDXCelldex Therapeutics2.7989 of 5 stars$26.210.0%N/A-15.3%$1.74B$9.98M-10.20160Insider BuyingDVAXDynavax Technologies4.6463 of 5 stars$13.66+5.0%N/A-9.8%$1.70B$249.69M105.09408Short Interest ↑High Trading VolumeBCRXBioCryst Pharmaceuticals4.2114 of 5 stars$8.19+5.3%N/A+36.8%$1.70B$331.41M-13.43530Short Interest ↓MYGNMyriad Genetics4.3033 of 5 stars$17.31-0.6%N/A-11.4%$1.58B$802.20M-13.322,700Analyst UpgradeNews CoverageNVAXNovavax3.7299 of 5 stars$9.01+1.1%N/A+25.6%$1.44B$983.71M-3.261,543Earnings ReportAnalyst ForecastAnalyst RevisionNews Coverage Related Companies and Tools Related Companies ADAP Alternatives CLLS Alternatives BLUE Alternatives ATRA Alternatives MNKD Alternatives CLDX Alternatives DVAX Alternatives BCRX Alternatives MYGN Alternatives NVAX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SGMO) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sangamo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sangamo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SGMO Stock Alerts